ASR Nederland N.V. (AMS:ASRNL)
64.36
+0.36 (0.56%)
Apr 28, 2026, 5:35 PM CET
ASR Nederland Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Premiums & Annuity Revenue | 10,324 | 9,601 | 8,095 | 5,437 | 5,777 | Upgrade
|
| Total Interest & Dividend Income | 10,340 | 618 | -1,074 | 13,544 | 3,207 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1,200 | 195 | 1,053 | -4,967 | 448 | Upgrade
|
| Other Revenue | -2,340 | 4,693 | 4,449 | -10,054 | 283 | Upgrade
|
| Total Revenue | 17,124 | 15,107 | 12,523 | 3,960 | 9,715 | Upgrade
|
| Revenue Growth (YoY) | 13.35% | 20.63% | 216.24% | -59.24% | 28.01% | Upgrade
|
| Policy Benefits | 8,219 | 7,460 | 6,427 | 4,537 | 6,817 | Upgrade
|
| Policy Acquisition & Underwriting Costs | - | - | - | - | 526 | Upgrade
|
| Selling, General & Administrative | 1,574 | 1,555 | 1,373 | 1,120 | 725 | Upgrade
|
| Other Operating Expenses | 845 | 818 | 914 | 273 | 160 | Upgrade
|
| Total Operating Expenses | 10,813 | 10,009 | 8,856 | 5,965 | 8,249 | Upgrade
|
| Operating Income | 6,311 | 5,098 | 3,667 | -2,005 | 1,466 | Upgrade
|
| Interest Expense | -351 | -446 | -269 | -95 | -342 | Upgrade
|
| Currency Exchange Gain (Loss) | 11 | -2 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -5,468 | -3,394 | -2,015 | -307 | 32 | Upgrade
|
| EBT Excluding Unusual Items | 503 | 1,256 | 1,383 | -2,407 | 1,156 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | -4 | Upgrade
|
| Impairment of Goodwill | - | - | -13 | - | -9 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -33 | -26 | Upgrade
|
| Asset Writedown | 193 | 208 | -91 | 117 | 92 | Upgrade
|
| Pretax Income | 696 | 1,464 | 1,279 | -2,323 | 1,209 | Upgrade
|
| Income Tax Expense | 131 | 387 | 275 | -606 | 270 | Upgrade
|
| Earnings From Continuing Ops. | 565 | 1,077 | 1,004 | -1,717 | 939 | Upgrade
|
| Earnings From Discontinued Ops. | - | -121 | 82 | - | - | Upgrade
|
| Net Income to Company | 565 | 956 | 1,086 | -1,717 | 939 | Upgrade
|
| Minority Interest in Earnings | -17 | 2 | - | 8 | 3 | Upgrade
|
| Net Income | 548 | 958 | 1,086 | -1,709 | 942 | Upgrade
|
| Preferred Dividends & Other Adjustments | 72 | 63 | 48 | 48 | 48 | Upgrade
|
| Net Income to Common | 476 | 895 | 1,038 | -1,757 | 894 | Upgrade
|
| Net Income Growth | -42.80% | -11.79% | - | - | 43.38% | Upgrade
|
| Shares Outstanding (Basic) | 206 | 211 | 179 | 137 | 136 | Upgrade
|
| Shares Outstanding (Diluted) | 228 | 232 | 200 | 137 | 158 | Upgrade
|
| Shares Change (YoY) | -1.87% | 15.94% | 46.33% | -13.24% | -1.65% | Upgrade
|
| EPS (Basic) | 2.31 | 4.25 | 5.80 | -12.82 | 6.56 | Upgrade
|
| EPS (Diluted) | 2.16 | 3.92 | 5.26 | -12.82 | 5.77 | Upgrade
|
| EPS Growth | -44.85% | -25.52% | - | - | 47.98% | Upgrade
|
| Free Cash Flow | -587 | -724 | 3,568 | -1,140 | -188 | Upgrade
|
| Free Cash Flow Per Share | -2.57 | -3.12 | 17.80 | -8.32 | -1.19 | Upgrade
|
| Dividend Per Share | 3.410 | 3.120 | 2.890 | 2.700 | 2.420 | Upgrade
|
| Dividend Growth | 9.29% | 7.96% | 7.04% | 11.57% | 18.63% | Upgrade
|
| Operating Margin | 36.85% | 33.75% | 29.28% | -50.63% | 15.09% | Upgrade
|
| Profit Margin | 2.78% | 5.92% | 8.29% | -44.37% | 9.20% | Upgrade
|
| Free Cash Flow Margin | -3.43% | -4.79% | 28.49% | -28.79% | -1.93% | Upgrade
|
| EBITDA | 6,452 | 5,211 | 3,745 | -1,957 | 1,496 | Upgrade
|
| EBITDA Margin | 37.68% | 34.49% | 29.90% | -49.42% | 15.40% | Upgrade
|
| D&A For EBITDA | 141 | 113 | 78 | 48 | 30 | Upgrade
|
| EBIT | 6,311 | 5,098 | 3,667 | -2,005 | 1,466 | Upgrade
|
| EBIT Margin | 36.85% | 33.75% | 29.28% | -50.63% | 15.09% | Upgrade
|
| Effective Tax Rate | 18.82% | 26.43% | 21.50% | - | 22.33% | Upgrade
|
| Revenue as Reported | - | - | - | - | 10,036 | Upgrade
|
Source: S&P Capital IQ. Insurance template. Financial Sources.